Уважаемые коллеги, доброго времени суток! Представляем вам швейцарское научное издание American Journal of Nephrology. Журнал имеет первый квартиль, издаётся в S. Karger AG, его SJR за 2021 г. равен 1,391, импакт-фактор 4,605, печатный ISSN - 0250-8095, электронный - 1421-9670, предметная область Нефрология. Вот так выглядит обложка:
Редактором является Джордж Бакрис, контактные данные - gbakris@uchicago.edu, bbrisky@medicine.bsd.uchicago.edu.
Это рецензируемый журнал, который фокусируется на актуальных темах как фундаментальной науки, так и клинических исследований. Статьи разделены на несколько разделов, включая:
- Оригинальные отчеты, охватывающие клинические, фундаментальные исследования и исходы;
- Углубленные тематические обзоры по конкретным темам, выбранным редактором и младшими редакторами;
- Приглашенные дебаты - отобранные по "актуальным темам", определенным редакционной коллегией.
Адрес издания - https://www.karger.com/Journal/Home/223979
Пример статьи, название - Clinical Outcomes of Persistent Severe Acute Kidney Injury among Patients with Kidney Disease Improving Global Outcomes Stage 2 or 3 Acute Kidney Injury. Заголовок (Abstract)
Introduction: The burden of persistent (≥3 days) severe AKI (PS-AKI) is poorly described among inpatients with stage 2–3 AKI in the ward or ICU. Quantification could motivate targeted interventions to decrease duration of AKI in these high-risk patients. Methods: This retrospective cohort study included adult patients discharged from January 1, 2017, to December 31, 2019, from US hospitals in the PINC AI Healthcare Database. Patients with KDIGO stage 2 or 3 AKI, length of stay ≥3 days, ≥3 serum creatinine measures, and no history of renal transplant, dialysis, or stage 5 chronic kidney disease were included. Patients were classified as PS-AKI (stage 3 AKI lasting ≥3 days or with death in ≤3 days, or stage 2 or 3 AKI with dialysis in ≤3 days) or not PS-AKI (NPS-AKI) (stage 3 AKI for ≤2 days, or stage 2 AKI without dialysis in ≤3 days). Outcomes during index (initial) hospitalization were PS-AKI incidence, ICU use, and in-hospital mortality, and during 30 days post-discharge were readmissions, in-hospital mortality, dialysis, and “new” dialysis (dialysis among patients without dialysis during index hospitalization). For index outcomes, we used a sensitivity definition, PS-AKISens, that excluded patients who met PS-AKI criteria by dialysis/death in ≤3 days of AKI onset. Multivariable-adjusted logistic regression quantified differences between PS-AKI and NPS-AKI, overall, and separately for ICU and non-ICU patients. Results: Among 126,528 inpatients with stage 2 or 3 AKI, PS-AKI developed in 24.4% (30,916), with 39% of PS-AKI occurring in non-ICU patients. With NPS-AKI as the reference group, adjusted odds ratios (aORs) (95% CI) for PS-AKI and for PS-AKISens were 2.15 (2.09–2.21) and 1.28 (1.24–1.32) for ICU use and 4.58 (4.41–4.75) and 1.79 (1.70–1.89) for in-hospital mortality during index hospitalization. For outcomes during 30 days post-discharge, aORs for PS-AKI versus NPS-AKI were 1.07 (1.02–1.11) for readmissions, 1.33 (1.18–1.49) for in-hospital mortality, 15.66 (13.87–17.67) for dialysis, and 6.80 (5.84–7.93) for new dialysis. Despite higher mortality among ICU patients, aORs for outcomes during index and 30 days post-discharge were similar for ICU and non-ICU patients. Conclusion: In and out of the ICU, PS-AKI frequently affected inpatients with stage 2 or 3 AKI and was independently associated with worse clinical outcomes during index hospitalization and during 30 days post-discharge. These results suggest that interventions to prevent persistence of severe AKI may reduce adverse clinical outcomes among patients with stage 2 or 3 AKI in or out of the ICU.